Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01219387 · ClinicalTrials.gov registry record

Evaluation of Anti-mullerian Hormone Levels as Predictive of IVF Outcomes in Women Over 38 Years Old

A clinical trial, sponsored by Reproductive Medicine Associates of New Jersey.

Completed
Registry status
300
Enrollment target

NCT01219387: Completed study, sponsored by Reproductive Medicine Associates of New Jersey.

NCT01219387 is a clinical trial that has completed, run by Reproductive Medicine Associates of New Jersey. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01219387 has completed, sponsored by Reproductive Medicine Associates of New Jersey.

COMPLETED
Registry status
300 participants
Enrollment target

Study Summary

The present study is designed to evaluate the basal serum levels of anti-mullerian hormone (AMH) and inhibin B as early predictors of ovarian response, implantation rate, and pregnancy rate in women 38 years old or older that are undergoing an IVF cycle.

Primary Outcome

Evaluate the relationship between a patients AMH and inhibin level prior to beginning IVF treatment and the oocyte quality as observed during the IVF cycle

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2006-02
Est. Completion 2010-06

What the finished NCT01219387 record still lists

NCT01219387 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT01219387 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01219387 about?

NCT01219387 is a clinical study titled "Evaluation of Anti-mullerian Hormone Levels as Predictive of IVF Outcomes in Women Over 38 Years Old". The present study is designed to evaluate the basal serum levels of anti-mullerian hormone (AMH) and inhibin B as early predictors of ovarian response, implantation rate, and pregnancy rate in women 38 years old or older that are undergoing an IVF cycle.

What is the current status of trial NCT01219387?

This trial is currently completed. The enrollment target is 300 participants. The study started on 2006-02. Estimated completion is 2010-06.

Who is sponsoring clinical trial NCT01219387?

This trial is sponsored by Reproductive Medicine Associates of New Jersey, which has 51 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01219387, the US trial registry maintained by the National Library of Medicine. NCT01219387 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.